Literature DB >> 24719020

Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma.

Shinji Itoh1, Ken Shirabe, Yoshihiro Matsumoto, Shohei Yoshiya, Jun Muto, Norifumi Harimoto, Yo-Ichi Yamashita, Toru Ikegami, Tomoharu Yoshizumi, Akihiro Nishie, Yoshihiko Maehara.   

Abstract

PURPOSE: To evaluate the effect of body composition on outcomes after hepatic resection for patients with hepatocellular carcinoma (HCC).
METHODS: We performed 190 hepatic resections for HCC and divided the patients into 2 groups on the basis of visceral fat area (VFA), assessed by computed tomographic measurement at the level of the umbilicus, into high VFA (H-VFA) (n = 106) and low VFA (L-VFA) (n = 84) groups. We compared the surgical outcomes between the two groups.
RESULTS: L-VFA was significantly correlated with a lower body mass index, sarcopenia, lower serum albumin, and liver cirrhosis. There was no difference in the incidence of postoperative complications and mortality between the 2 groups. Patients in the L-VFA group had a significantly poorer prognosis than those in the H-VFA group in terms of both overall (P = 0.043) and recurrence-free (P = 0.001) survival. The results of multivariate analysis showed that sarcopenia rather than L-VFA was an independent and prognostic indicator after hepatic resection with HCC.
CONCLUSIONS: Body composition is an important factor affecting cancer outcomes after hepatic resection for HCC in Japan.

Entities:  

Mesh:

Year:  2014        PMID: 24719020     DOI: 10.1245/s10434-014-3686-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  40 in total

1.  Sarcopenia is an independent predictor of complications after colorectal cancer surgery.

Authors:  Ryota Nakanishi; Eiji Oki; Shun Sasaki; Kosuke Hirose; Tomoko Jogo; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Kensuke Kudo; Junji Kurashige; Masahiko Sugiyama; Yuichiro Nakashima; Kippei Ohgaki; Hiroshi Saeki; Yoshihiko Maehara
Journal:  Surg Today       Date:  2017-07-11       Impact factor: 2.549

2.  Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma.

Authors:  Savita Joglekar; Aeen Asghar; Sarah L Mott; Benjamin E Johnson; Anna M Button; Eve Clark; James J Mezhir
Journal:  J Surg Oncol       Date:  2014-12-29       Impact factor: 3.454

3.  Sarcopenia with systemic inflammation can predict survival in patients with hepatocellular carcinoma undergoing curative resection.

Authors:  Hanbaro Kim; Han Zo Choi; Ji Min Choi; Byung Mo Kang; Jung Woo Lee; Ji Woong Hwang
Journal:  J Gastrointest Oncol       Date:  2022-04

Review 4.  Adiposity and cancer survival: a systematic review and meta-analysis.

Authors:  Elizabeth M Cespedes Feliciano; Bette J Caan; En Cheng; Jocelyn Kirley
Journal:  Cancer Causes Control       Date:  2022-08-15       Impact factor: 2.532

5.  Slow Gait Speed Is a Risk Factor for Complications After Hepatic Resection.

Authors:  Shinji Itoh; Tomoharu Yoshizumi; Kazuhisa Sakata; Takashi Motomura; Yohei Mano; Takeo Toshima; Norifumi Harimoto; Noboru Harada; Toru Ikegami; Yuji Soejima; Ryuichi Kusaba; Takahide Kamishima; Akihiro Nishie; Yoshihiko Maehara
Journal:  J Gastrointest Surg       Date:  2018-10-08       Impact factor: 3.452

Review 6.  Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Ke-Vin Chang; Jin-De Chen; Wei-Ting Wu; Kuo-Chin Huang; Chia-Tzu Hsu; Der-Sheng Han
Journal:  Liver Cancer       Date:  2017-12-09       Impact factor: 11.740

7.  Prognostic value and association of sarcopenic obesity and systemic inflammatory indexes in patients with hepatocellular carcinoma following hepatectomy and the establishment of novel predictive nomograms.

Authors:  Chengyu Liao; Ge Li; Yannan Bai; Songqiang Zhou; Long Huang; Maolin Yan; Funan Qiu; Jiangzhi Chen; Yaodong Wang; Yifeng Tian; Shi Chen
Journal:  J Gastrointest Oncol       Date:  2021-04

8.  Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment.

Authors:  Giulio Antonelli; Elia Gigante; Massimo Iavarone; Paola Begini; Angelo Sangiovanni; Elsa Iannicelli; Piero Biondetti; Adriano M Pellicelli; Lucia Miglioresi; Paolo Marchetti; Pietro Lampertico; Massimo Marignani
Journal:  United European Gastroenterol J       Date:  2018-05-31       Impact factor: 4.623

9.  No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma.

Authors:  Issei Saeki; Takahiro Yamasaki; Masaki Maeda; Reo Kawano; Takuro Hisanaga; Takuya Iwamoto; Toshihiko Matsumoto; Isao Hidaka; Tsuyoshi Ishikawa; Taro Takami; Isao Sakaida
Journal:  Liver Cancer       Date:  2018-04-06       Impact factor: 11.740

10.  Impact and risk factors for skeletal muscle mass loss after hepatic resection in patients with hepatocellular carcinoma.

Authors:  Shinji Itoh; Tomoharu Yoshizumi; Takahiro Tomiyama; Norifumi Iseda; Akinari Morinaga; Tomonari Shimagaki; Huanlin Wang; Takeshi Kurihara; Yoshihiro Nagao; Takeo Toshima; Noboru Harada; Akihiro Nishie; Kousei Ishigami; Masaki Mori
Journal:  JGH Open       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.